Advanced-generation macrolides: tissue-directed antibiotics.
about
Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to AntibioticsFrom Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials.Azithromycin effectiveness against intracellular infections of Francisella.Azithromycin decreases crevicular fluid volume and mediator content.Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients.Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort studyAzithromycin inhibits IL-1 secretion and non-canonical inflammasome activation.Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens.Macrolides in cystic fibrosis.Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.Clinical implications of macrolide resistance in community-acquired respiratory tract infections.Biotic acts of antibioticsAdvances in immobilized artificial membrane (IAM) chromatography for novel drug discovery.Pharmacokinetic and pharmacodynamic integration and modeling of acetylkitasamycin in swine for Clostridium perfringens.Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense.Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease in multisource commingled feedlot cattle.Bartonella vinsonii subspecies berkhoffi as a possible cause of anterior uveitis and choroiditis in a dog.The influence of Actinobacillus pleuropneumoniae infection on tulathromycin pharmacokinetics and lung tissue disposition in pigs.Azithromycin: assessment of intrinsic cytotoxic effects on corneal epithelial cell cultures.Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections.Gammopathy in a Spanish dog infected with Bartonella henselae.Azithromycin inhibits IL-5 production of T helper type 2 cells from asthmatic children.
P2860
Q22242242-C3CDCF61-0717-4FBE-82A6-C0334AB9DED2Q27687259-996D340B-0F67-45A1-A6DC-BE77620DAF02Q30435916-592D7AE7-1E32-4595-86F5-6DEC40646694Q34014517-A6E82AF9-2AD4-4D15-B86F-09E33E54B7F8Q34106668-474E77A9-0B6C-467E-ADB1-567D7B65A617Q34108761-1E6D8AC4-B4B3-4F1F-B4F6-EB3389CB8C31Q34769319-9FE52AFD-CD94-4E13-9D3C-0397B94CF1B1Q35190494-499C6D7D-D62C-4D86-A53B-C3EBFEF0F284Q35830510-9AB2F960-2580-4423-9A86-D4452DC965B8Q35947509-12A62682-5C5E-475B-B63E-68443BE02851Q36309930-ACA76BA1-A644-43E7-9C21-42FD5F916784Q36338455-A9D81A9B-DF22-4AAE-A07A-D6A90B526074Q36688947-F80C7736-625E-45A4-A7F2-9003AA45F116Q37101851-07A1C03A-78C1-42E5-A0F2-7BA1EEF9E051Q38769803-7A701EC5-653F-4879-9689-ECA5A1328920Q38808661-F6B30E12-2AE3-45CE-9BEE-0A9C6EAAAD19Q39766949-DC5F435E-76A7-4483-87D1-E4E9C8903544Q39769151-9654098E-4A26-4711-A794-7FA26EE5B18BQ40397182-E215BF5A-309E-4FC3-A16A-DCAEC9BF9DECQ40461646-6FE814AC-2DEB-44F4-B4DB-5A1277C0029FQ40546933-B846A4E1-04A1-4880-930A-98FF3EF57F26Q41054410-10E84445-79D7-403C-B11C-393CF0616E67Q41226009-F658625F-5845-4E19-883A-E07450388E7AQ41267412-B976DF30-C57A-4ED5-8934-9CC68C30928AQ41887195-74C48BB4-D8CF-4C6F-87A0-B7EC452D3EDEQ41969496-F6C5A28E-24A8-4D22-9FE2-7716BCD559E9Q42789151-AB621772-E0BC-4650-A4FA-957BF027501BQ51415937-3CC02FB9-7D45-44B3-BEA0-C5B77F3B052DQ53246710-1BBC31DC-0C75-4262-9D6B-E637206E3A31
P2860
Advanced-generation macrolides: tissue-directed antibiotics.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Advanced-generation macrolides: tissue-directed antibiotics.
@ast
Advanced-generation macrolides: tissue-directed antibiotics.
@en
Advanced-generation macrolides: tissue-directed antibiotics.
@nl
type
label
Advanced-generation macrolides: tissue-directed antibiotics.
@ast
Advanced-generation macrolides: tissue-directed antibiotics.
@en
Advanced-generation macrolides: tissue-directed antibiotics.
@nl
prefLabel
Advanced-generation macrolides: tissue-directed antibiotics.
@ast
Advanced-generation macrolides: tissue-directed antibiotics.
@en
Advanced-generation macrolides: tissue-directed antibiotics.
@nl
P1476
Advanced-generation macrolides: tissue-directed antibiotics.
@en
P2093
P356
10.1016/S0924-8579(01)00410-1
P478
18 Suppl 1
P577
2001-01-01T00:00:00Z